v3.22.2.2
Note 9 - Stockholders' Deficit
 9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

9. Stockholders’ Deficit

 

The Company has granted options to employees and Board members to purchase shares of common stock. The following is a summary of option award activity during the nine months ended September 30, 2022:

    

  

Total Stock Options Outstanding

  Weighted Average Exercise Price per Share 

December 31, 2021

  45,468  $14.28 

Granted

  1,216,149   0.24 

Vested

  —   — 

Forfeited, Canceled

  (27,090)  14.89 

September 30, 2022

  1,234,527  $0.44 

 

The following is a summary of outstanding stock options as of September 30, 2022:

 

  

As of September 30, 2022

 
  Stock Options Outstanding  Vested Stock Options 

Quantity

  1,234,527   1,234,527 

Weighted Average Exercise Price

 $0.44  $0.44 

Weighted Average Remaining Contractual Term (in Years)

  9.90   9.90 

Intrinsic Value

 $—  $— 

 

As of September 30, 2022, there was no total compensation cost not yet recognized related to unvested stock options.

 

As of September 30, 2022, there are 567,640 restricted stock units outstanding to employees, 507,574 from the Old Cytocom plan and 60,066 included in the Plan.